Medpace Holdings Inc is a global contract research organization (CRO) that specializes in providing a range of services to the pharmaceutical and biotechnology industries
The company supports clients throughout the drug development process, offering expertise in clinical trials, regulatory compliance, and data management. Medpace focuses on delivering efficient and high-quality clinical services across various therapeutic areas, helping to streamline the path from clinical research to market approval. Through its integrated approach, the company aims to accelerate the development of new treatments while ensuring adherence to safety and regulatory standards.
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSECRL) and its peers.
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period.
Shares of clinical research company Medpace Holdings (NASDAQMEDP)
fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and EBITDA guidance fell short of Wall Street's estimates. The weaker-than-expected outlook suggests slowing business momentum, as reflected in the declining book-to-bill ratio of 0.99x. On the other hand, the company exceeded analysts' EPS and EBITDA expectations this quarter.Overall, this quarter could have been better.
Clinical research company Medpace Holdings (NASDAQMEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s full-year revenue guidance of $2.16 billion at the midpoint came in 3.5% below analysts’ estimates. Its GAAP profit of $3.67 per share was 24.1% above analysts’ consensus estimates.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
